← Leaderboards
Rahul Anil Sheth
University Of Tx Md Anderson Can Ctr
$2,509,641
Attributed
$3,506,540
Total exposure
3
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.1M · FY2019–25$2M$1.5M$1M$500K$0
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$3,506,540 · 3
By mechanism
R01$1,495,349 · 1
R37$1,371,191 · 1
R21$640,000 · 1
Top collaborators
- Vahid Afshar-Kharghan3 shared
- Anil K Sood3 shared
Most similar at University Of Tx Md Anderson Can Ctr
Same institution · by research overlap
- Vahid Afshar-Kharghan$3,543,397
- Anil K Sood$29,572,737
- Erik Sulman$6,610,770
- Krishna Pl Bhat$3,427,143
Others in their field
Other Emerging Leaders on “Tumor”
- Leonard Freedman · Leidos Biomedical Research, Inc.$360,535,780
- Lynn Briscoe · Leidos Biomedical Research, Inc.$120,794,323
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$105,180,681
- Leonard Freedmand · Leidos Biomedical Research, Inc.$78,762,245
- Connie Suders · Leidos Biomedical Research, Inc.$67,882,919
- Gautam (george) Mitra · Leidos Biomedical Research, Inc.$53,523,213
Research focus
TumorGenerationsMortalityPreventMalignant NeoplasmsPharmaceutical PreparationsImmunotherapyChemotherapyHyperthermiaImmune ResponseInnovationMinimally InvasiveMouse ModelNormal Tissue MorphologyCancer TherapyCancer EtiologyBloodCessation Of LifeFoundationsCellsImmuneImmune ActivationClinical TrialsInjections
Grant awards (9)
An image-guided immunotherapy and hyperthermia delivery device to overcome barriers to tumor immunity for advanced hepatocellular carcinoma$464,218
R37 · FY2025 · CA · contact PI
Novel Biomarkers Predicting Blood Clots in Ovarian Cancer$441,654
R01 · FY2025 · CA
An image-guided immunotherapy and hyperthermia delivery device to overcome barriers to tumor immunity for advanced hepatocellular carcinoma$446,342
R37 · FY2024 · CA · contact PI
Novel Biomarkers Predicting Blood Clots in Ovarian Cancer$419,571
R01 · FY2024 · CA
Novel Biomarkers Predicting Blood Clots in Ovarian Cancer$634,124
R01 · FY2023 · CA
An image-guided immunotherapy and hyperthermia delivery device to overcome barriers to tumor immunity for advanced hepatocellular carcinoma$460,631
R37 · FY2023 · CA · contact PI
Molecularly targeted photothermal ablation to enhance the therapeutic efficacy of immunomodulatory therapies in hepatocellular carcinoma$200,000
R21 · FY2021 · EB · contact PI
Molecularly targeted photothermal ablation to enhance the therapeutic efficacy of immunomodulatory therapies in hepatocellular carcinoma$200,000
R21 · FY2020 · EB · contact PI
Molecularly targeted photothermal ablation to enhance the therapeutic efficacy of immunomodulatory therapies in hepatocellular carcinoma$240,000
R21 · FY2019 · EB · contact PI